fr

EN DE

fr

EN DE

Publications

1959 PUBLICATIONS - effacer la recherche

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

2022

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

de Mathelin P

Sarcopenia remaining after intensive nutritional feeding support could be a criterion for the selection of patients for surgery for oesogastric junction adenocarcinoma.

2022

Pharmaceutics

Dias AMM

Superparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia.

2022

European journal of oncology nursing : the official journal of European Oncology Nursing Society

Nguyen JM

Oncology health professionals' perspectives of determinants of exercise by cancer patients: A socio-ecological approach.

2022

Biomedicines

Lopez T

Wound Healing versus Metastasis: Role of Oxidative Stress.

2022

The Lancet regional health. Europe

Debieuvre D

Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.

2022

Artificial intelligence in medicine

Ben Hamida A

Weakly Supervised Learning using Attention gates for colon cancer histopathological image segmentation.

2022

Cancers

Hudry D

Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.

2022

Virchows Archiv : an international journal of pathology

Wolf T

All pineal tumors expressing germ cell tumor markers are not necessarily germ cell tumors: histopathological and molecular study of a midline primary intracranial sarcoma DICER1-mutant.

2022

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Decorads CE

Routine first-line detection of breast cancer therapy-related cardiotoxicity by serial, fast and ultra-low-dose equilibrium radionuclide angiography.

2022

Journal of hepatology

Roehlen N

Treatment of HCC with Claudin-1 specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.